Keywords: Ono Pharma, Onyx Pharma, Carfilzomib, ONX 0912, Licensing, Japan, Multiple melanoma
Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
Article | 09 September 2010
California, USA-based drugmaker Onyx Pharmaceuticals (Nasdaq:ONXX) has entered into an exclusive agreement with Ono Pharmaceutical (TYO: 4528) to develop and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
